Olema Pharmaceuticals Files 8-K

Ticker: OLMA · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1750284

Olema Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyOlema Pharmaceuticals, INC. (OLMA)
Form Type8-K
Filed DateSep 27, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: reporting, sec-filing

Related Tickers: OLMA

TL;DR

Olema Pharma filed an 8-K, no major news, just routine reporting.

AI Summary

Olema Pharmaceuticals, Inc. filed an 8-K on September 27, 2024, to report on other events and financial statements. The filing does not contain specific details about new material events, significant financial changes, or executive actions beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates Olema Pharmaceuticals is fulfilling its reporting obligations with the SEC, but it does not disclose any new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would suggest an immediate change in risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Olema Pharmaceuticals?

The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 27, 2024.

Does this filing disclose any new material events or agreements?

The filing indicates it is for 'Other Events' and does not explicitly detail any new material events or agreements beyond standard reporting requirements.

What is Olema Pharmaceuticals' principal executive office address?

Olema Pharmaceuticals' principal executive office is located at 780 Brannan Street, San Francisco, California, 94103.

What is the Commission File Number for Olema Pharmaceuticals?

The Commission File Number for Olema Pharmaceuticals is 001-39712.

When is Olema Pharmaceuticals' fiscal year end?

Olema Pharmaceuticals' fiscal year ends on December 31.

Filing Stats: 865 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2024-09-27 07:00:15

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 27, 2024, Olema Pharmaceuticals, Inc. (the "Company" or "Olema") posted a corporate presentation to its website that will be shared with investors and others from time to time. A copy of this presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The Company plans to present non-clinical data for OP-3136, the Company's development candidate targeting KAT6, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ("ENA"), which will be held October 23-25, 2024. An initial new drug ("IND") application for OP-3136 is anticipated to be submitted in the fourth quarter of 2024 and the Phase 1/2 clinical study for OP-3136 is anticipated to begin in 2025. The Company is also planning for a potential initiation of OPERA-02, a proposed Phase 3 clinical trial of palazestrant in combination with a CDK4/6 inhibitor, ribociclib, in 2025.

Forward Looking Statements

Forward Looking Statements

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation, dated September 27, 2024, of Olema Pharmaceuticals, Inc . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OLEMA PHARMACEUTICALS, INC. Date: September 27, 2024 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing